DealBook Briefing: Welcome to the Trade War


More on why the retailer is following other companies and speaking out on hot-button topics, from Sarah Nassauer of the WSJ:

Today, around 72% of Walmart shoppers want the company to “take a stand on important social issues” and 85% want the retailer to “make it clear what values you stand for,” said Walmart’s chief marketing officer, Tony Rogers, in a June presentation to reporters, citing a survey by research firm Kantar.

Finding the right balance is tricky: One customer complained to the WSJ about not being able to buy ammo from Walmart anymore, and said he had urged his friends to boycott the retailer.

There may be a better recession indicator than the yield curve

For years, the Fed has used the yield curve — which tracks the payouts from Treasury securities of different repayment periods — as a barometer of economic health. But it’s now reconsidering whether the tool is a useful predictor of recessions.

Economists worry that the yield curve could soon invert — when the yields of two-year Treasury notes rise above those of 10-year notes, the reverse of the norm. Historically, that’s been a sign of economic trouble. But there are other reasons for an inverted yield curve, including the Fed’s interest-rate policies.

So the central bank has started looking at other indicators, including the interest rate used in the federal funds market. Whether that’s a more useful tool, however, remains an open question.


Credit Jason Reed/Reuters

Big Pharma has been paying F.D.A. doctors after drugs get approved

If drug companies give money to physicians before they sit on a Food and Drug Administration panel to approve a therapy, it would clearly look like a conflict of interest. But what if payments come after?

The journal Science found that to be more common than one might think:

In examining compensation records from drug companies to physicians who advised FDA on whether to approve 28 psychopharmacologic, arthritis, and cardiac or renal drugs between 2008 and 2014, Science found widespread after-the-fact payments or research support to panel members.

The situation is ethically troubling, regardless of the time of payment, especially since the sums can amount to millions of dollars. But Science says that the F.D.A.’s safeguards “are not designed to prevent such future financial ties.”


Drew Faust Credit Michael Dwyer/Associated Press

Revolving door

Drew Faust, the former president of Harvard, has joined the board of Goldman Sachs. (Goldman)

Three former executives from Social Capital — Arjun Sethi, Ted Maidenberg and Jonathan Hsu — have started their own venture fund. (Business Insider)

Heinrich Hiesinger stepped down as ThyssenKrupp’s C.E.O., days after the company announced a merger with Tata Steel. (FT)

The speed read


• Boeing agreed to buy control of Embraer’s commercial-jets business for $3.8 billion, in a move to build smaller planes. (NYT)

• Singapore’s competition regulator threatened to unwind a merger of Uber’s Southeast Asian business with Grab, over antitrust concerns. (WSJ)

• Glencore is buying back $1 billion worth of its shares to shore up its stock price after it disclosed that it had been subpoenaed by the Justice Department. (FT)

• Steven Cohen has been blocked from accepting British investors in his new hedge fund. (FT)

Politics and policy

• Michael Cohen has hired Lanny Davis, a lawyer who helped defend President Bill Clinton during his impeachment hearings, as an adviser. (NYT)

• What President Trump is looking for in his next Supreme Court nominee. (Politico)


• Amazon is threatening another industry: advertising. (NBC)

• Tech giants succeeded in shooting down a bill in Europe that would have imposed some of the world’s strictest copyright laws. (NYT)

• California is still trying to enact its own net neutrality bill. (Verge)

• Samsung predicts that its record-breaking earnings streak might come to an end. (WSJ)

Best of the rest

• How much patience does the White House have for a hawkish Fed? (DealBook)

• It’s getting harder for employers to fill jobs. (CNBC)

• U.S. regulators fined Credit Suisse $77 million for hiring relatives of powerful Chinese officials to win business. (NYT)

• Hop into an Uber, hop out with a new business plan: Is ride-sharing the new LinkedIn? (NYT)

We’d love your feedback. Please email thoughts and suggestions to

Continue reading the main story


Please enter your comment!
Please enter your name here